(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 May 2022 (19.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/101165 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61K 47/26* (2006.01)
A61K 47/10 (2017.01) *A61K 9/00* (2006.01)
A61K 47/12 (2006.01) *A61K 9/19* (2006.01)
A61K 47/18 (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2021/081038

(22) International Filing Date:
09 November 2021 (09.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20315449.7 10 November 2020 (10.11.2020) EP

(71) Applicant: **SANOFI** [FR/FR]; 54 rue La Boétie, 75008 PARIS (FR).

(72) Inventors: **AUTHELIN, Jean-René**; c/o Sanofi, Patent Department, 54, rue la Boétie, 75008 PARIS (FR). **BENSAID, Fethi**; c/o Sanofi, Patent Department, 54, rue la Boétie, 75008 PARIS (FR). **BONESTEBE, Audrey**; c/o Sanofi, Patent Department, 54, rue la Boétie, 75008 PARIS (FR). **HUILLE, Sylvain**; c/o Sanofi, Patent Department, 54, rue la Boétie, 75008 PARIS (FR). **LEMAN, Marie**; c/o Sanofi, Patent Department, 54, rue la Boétie, 75008 PARIS (FR). **MANACHE-ALBERICI, Lucie**; c/o Sanofi, Patent Department, 54, rue la Boétie, 75008 PARIS (FR).

(74) Agent: **CABINET NONY**; 11 rue Saint-Georges, 75009 PARIS (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: CEACAM5 ANTIBODY-DRUG CONJUGATE FORMULATION

(57) Abstract: Provided are stabilized formulations of the human carcinoembryonic antigen-related cell adhesion molecule 5 (hCEACAM5)-targeted antibody-drug conjugate huMAb2-3-SPDB-DM4, as well as methods for making and using same.

WO 2022/101165 A1